Highlights and hot topics from 2011 in Thrombosis and Haemostasis

References
1 Ylä-Herttuala S, Bentzon JF, Daemen M. et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost 2011; 106: 1-19.
2 Korte W, Cattaneo M, Chassot PG. et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105: 743-749.
3 Gorin L, Fauchier L, Nonin E. et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score1. Thromb Haemost 2010; 103: 833-840.
4 Roskell NS, Lip GY, Noack H. et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106-1115.
5 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
6 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-571.
7 Lip GY, Huber K, Andreotti F. et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28. [Erratum in: Thromb Haemost 2010; 104: 653.]
8 Kirchhof P, Lip GYH, Van Gelder IC. et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106: 1012-1019.
9 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
10 Megens RT, Kemmerich K, Pyta J. et al. Intravital imaging of phagocyte recruitment. Thromb Haemost 2011; 105: 802-810.
11 Zagorchev L, Mulligan-Kehoe MJ.. Advances in imaging angiogenesis and inflammation in atherosclerosis. Thromb Haemost 2011; 105: 820-827.
12 Quillard T, Croce K, Jaffer FA. et al. Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo. Thromb Haemost 2011; 105: 828-836.
13 Kawao N, Nagai N, Tamura Y. et al. Urokinase-type plasminogen activator contributes to heterogeneity of macrophages at the border of damaged site during liver repair in mice. Thromb Haemost 2011; 105: 892-900.
14 Gray C, Loynes CA, Whyte MK. et al. Simultaneous intravital imaging of macrophage and neutrophil behaviour during inflammation using a novel transgenic zebrafish. Thromb Haemost 2011; 105: 811-819.
15 Sibbing D, Byrne RA, Bernlochner I. et al. High platelet reactivity and clinical outcome – fact and fiction. Thromb Haemost 2011; 106: 191-202.
16 Ferreiro JL, Sibbing D, Angiolillo DJ.. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010; 103: 1128-1135.
17 Judge HM, Buckland RJ, Sugidachi A. et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217.
18 Becker RC, Gurbel PA.. Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost 2010; 103: 535-544.
19 Harmsze AM, Robijns K, van Werkum JW. et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103: 920-925.
20 Sofi F, Marcucci R, Gori AM. et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-848.
21 Korte W, Cattaneo M, Chassot PG. et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Peri-operative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105: 743-749.
22 Serebruany VL.. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
23 Wallentin L, Becker RC, James SK. et al. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. “Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified” (Thromb Haemost 2011; 105.5). Thromb Haemost 2011; 105: 760-762.
24 Ohman EM, Roe MT.. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany “Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified” (Thromb Haemost 2011; 105.5). Thromb Haemost 2011; 105: 763-765.
25 Manthey H, Zernecke A.. Dendritic cells in atherosclerosis: functions in immune regulation and beyond. Thromb Haemost 2011; 106: 772-778.
26 Hristov M, Weber C.. Differential role of monocyte subsets in atherosclerosis. Thromb Haemost 2011; 106: 757-762.
27 Lievens D, von Hundelshausen P.. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
28 Gerdes N, Zhu L, Ersoy M. et al. Platelets regulate CD4? T-cell differentiation via multiple chemokines in humans. Thromb Haemost 2011; 106: 353-362.
29 Mirabelli-Badenier M, Braunersreuther V, Viviani GL. et al. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost 2011; 105: 409-420.
30 Fischer S, Nishio M, Dadkhahi S. et al. Expression and localisation of vascular ribonucleases in endothelial cells. Thromb Haemost 2011; 105: 345-355.
31 Lawall H, Bramlage P, Amann B.. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost 2010; 103: 696-709.
32 Ahrens I, Lip GY, Peter K.. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
33 Olsson SB, Rasmussen LH, Tveit A. et al. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010; 103: 604-612.
34 Weitz JI, Connolly SJ, Patel I. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633-641.
35 Lip GY.. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683-685.
36 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
37 Pengo V, Crippa L, Falanga A. et al. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
38 Samama MM, Martinoli JL, LeFlem L. et al. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
39 Apostolakis S, Lip GY.. Stroke prevention in non-valvular atrial fibrillation: Can warfarin do better?. Thromb Haemost 2011; 106: 753-754.
40 Gallagher AM, Setakis E, Plumb JM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
41 Luxembourg B, Delev D, Geisen C. et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
42 Yuana Y, Bertina RM, Osanto S.. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011; 105: 396-408.
43 Thomas A, Lenglet S, Chaurand P. et al. Mass spectrometry for the evaluation of cardiovascular diseases based on proteomics and lipidomics. Thromb Haemost 2011; 106: 20-33.
44 Paniccia R, Antonucci E, Maggini N. et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104: 287-292.
45 Biere-Rafi S, Baarslag MA, Peters M. et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-278.
46 Roth L, Marschalek R, Oldenburg J. et al. Characterisation of two novel large F8 deletions in patients with severe haemophilia A and factor VIII inhibitors. Thromb Haemost 2011; 105: 279-284.